
estradiol 1mg / micronised progesterone 100mg capsules (Bijuve®)

Theramex UK Ltd

05 August 2022

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

estradiol / micronised progesterone (Bijuve®) is accepted for use within NHSScotland.

Indication under review: continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses. The experience in treating women older than 65 years is limited.

Estradiol / micronised progesterone (Bijuve®) offers an additional treatment choice of continuous combined hormone replacement therapy.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 29 April 2022.

**Chairman
Scottish Medicines Consortium**

Published 12 September 2022